Search Filters

Search Results

Found 14 results

510(k) Data Aggregation

    K Number
    K153412
    Device Name
    Sleep Profiler
    Date Cleared
    2016-03-14

    (110 days)

    Product Code
    Regulation Number
    882.1400
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Sleep Profiler is intended for use for the diagnostic evaluation by a physician to assess sleep quality and score sleep disordered breathing events in adults only. The Sleep Profiler is a software-only device to be used under the supervision of a clinician to analyze physiological signals and automatically score sleep study results; including the staging of sleep, detection of arousals, snoring and sleep disordered breathing events (obstructive apneas, hypopneas and respiratory event related arousals). Central and mixed apneas can be manually marked within the records.

    Device Description

    The Sleep Profiler is a software application that analyzes previously recorded physiological signals obtained during sleep. The Sleep Profiler software can analyze any EDF files acquired with the Advanced Brain Monitoring X4 System and the X8 System models SP40 and SP29. Automated algorithms are applied to the raw signals in order to derive additional signals and interpret the raw and derived signal information. The software automates recognition of: Sleep stages Rapid Eye Movement (REM) and nREM (N1, N2, N3) and wake, Heart/pulse rate, Snoring loudness, Sleep/wake, Head movement and position, Snoring, sympathetic, behavioral and cortical arousals, ECG,EOG, EMG waveform, SpO2, Airflow, Respiratory Effort, Apneas and Hypopneas, Oxygen desaturations. The software identifies and rejects periods with poor electroencephalography signal quality. The full disclosure recording of derived signals and automated analyses can be visually inspected and edited prior to the results being integrated into a sleep study report. Medical and history information can be input from a questionnaire. Responses are analyzed to provide a pre-test probability of Obstructive Sleep Apnea (OSA). The automated analyses of physiological data are integrated with the questionnaire data, medical and history information to provide a comprehensive report. Several report formats are available depending on whether the user has acquired more than one night of data, wishes to obtain a narrative summary report or provide patient reports. The Sleep Profiler software can be used as a stand-alone application for use on Microsoft Windows 7 & 8 operating system platforms (desktop model). Alternatively, the user interface (i.e., entry or editing of information) can be delivered via a web-portal (portal model). The capability to enter or edit patient information, call the application to generate a study report, and/or download a report is provided using either the desktop PC application or web-portal application. The same analysis and report generation software is used for both the desktop and web-portal applications.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study information for the Sleep Profiler device, based on the provided FDA 510(k) summary:

    1. Table of Acceptance Criteria and Reported Device Performance

    EndpointAcceptance Criteria (Equivalent to Predicate Device)Reported Device Performance (Sleep Profiler)
    AHI for OSA DiagnosisMinimum targeted positive likelihood ratios for AHI > 5 and AHI > 15 are 3.5 and 5.0 respectively (equivalent to predicate ARES).Overall AHI:
    • AHI ≥ 5: Positive Likelihood Ratio = 6.67
    • AHI ≥ 15: Positive Likelihood Ratio = 33.0
      REM AHI:
    • AHI ≥ 5: Positive Likelihood Ratio = 8.84
    • AHI ≥ 15: Positive Likelihood Ratio = 18.33
      (These values exceed the minimum targeted likelihood ratios indicating equivalence) |
      | Sleep Staging (Agreement with Expert Consensus) | Comparison of auto-detected staging to PSG results obtained by expert raters, showing equivalent agreement to the predicate Sleep Profiler (K130007). No specific numeric thresholds are explicitly stated as acceptance criteria, but generally high concordance is expected for substantial equivalence. | Overall (n=43 subjects, 3 raters):
    • Wake: Positive Agreement 0.73, Negative Agreement 0.94
    • N1: Positive Agreement 0.25, Negative Agreement 0.93
    • N2: Positive Agreement 0.77, Negative Agreement 0.84
    • N3: Positive Agreement 0.76, Negative Agreement 0.94
    • REM: Positive Agreement 0.74, Negative Agreement 0.97
      (The document states "met" for this endpoint by comparison to the predicate.) |

    2. Sample Sizes and Data Provenance for Test Set

    • Sample Size (for AHI/OSA detection): 60 subjects for overall AHI, 40 subjects for REM AHI.
    • Sample Size (for Sleep Staging): A subset of 43 subjects from the AHI study, with at least 4 hours of raw X8 diagnostic recording time.
    • Data Provenance: The document states "signals acquired with the X8 System concurrent to polysomnography (PSG)." This implies the data was prospectively collected for this evaluation, likely from a clinical setting, but the country of origin is not specified.

    3. Number of Experts and Qualifications for Ground Truth (Test Set)

    • Number of Experts:
      • For AHI/OSA detection: "one rater per study" for PSG results.
      • For Sleep Staging: "weighted majority agreement of three raters" for the 43-subject subset.
    • Qualifications of Experts: Not explicitly stated beyond being "rater(s)" for PSG and "expert scoring" for sleep staging. Standard practice for such studies would imply board-certified sleep technologists or physicians experienced in PSG scoring.

    4. Adjudication Method for the Test Set

    • For AHI/OSA detection: "one rater per study." This implies no formal adjudication/consensus process among multiple independent reviewers, as only a single rater's PSG results were used as ground truth for each case.
    • For Sleep Staging: "weighted majority agreement of three raters." This indicates an adjudication method where the consensus of three experts established the ground truth.

    5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

    • No MRMC comparative effectiveness study is explicitly described where human readers' performance with and without AI assistance is compared. The study primarily focuses on the standalone performance of the Sleep Profiler software against expert-scored PSG.

    6. Standalone Performance Study

    • Yes, a standalone study was performed. The "Sleep Profiler software accuracy was clinically validated with signals acquired with the X8 System concurrent to polysomnography (PSG)." The results presented for AHI and sleep staging are for the algorithm's performance without human intervention, compared to human-scored PSG.

    7. Type of Ground Truth Used

    • Expert Consensus / Human Scoring: The primary ground truth for both AHI detection and sleep staging was derived from Polysomnography (PSG) results scored by human experts/raters. For sleep staging, it was specifically based on the "weighted majority agreement of three raters."

    8. Sample Size for the Training Set

    • The document does not explicitly state the sample size used for the training set of the Sleep Profiler software. It describes the clinical validation study (test set) but not the development data.

    9. How Ground Truth for the Training Set Was Established

    • The document does not provide details on how the ground truth for the training set was established. Typically, for such devices, training data would also be derived from expert-scored PSG, similar to the test set, but this information is not included in the 510(k) summary.
    Ask a Question

    Ask a specific question about this device

    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The X8 System is intended for prescription use in the home, healthcare facility, or clinical research environment to acquire, record, transmit, and display physiological signals from adult patients. All X8 models (SP40, SP29, and XS29) acquire, record, transmit, and/or display electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG) signals, with optional accelerometer, acoustical, and photoplethysmographic signals. Model SP29 additionally includes a nasal pressure transducer and cannula (for airflow), thoracic and abdomen respiratory effort, and pulse rate and oxyhemoglobin saturation from the finger. The X8 system only acquires and displays physiological signals; no claims are being made for analysis of the acquired signals with respect to the accuracy, precision, and reliability.

    Device Description

    The X8 System is indicated for acquiring, recording/storing, transmitting, and displaying physiological data in patients. It can be used by patients in the home, healthcare facility, or clinical research environment. Patients can move within their home or healthcare environment without having to remove the device (e.g. walk to the restroom).

    The X8 System is comprised of the X8 device which is worn on the patient's head and body, accessories, the Device Manager software, and the X-Series Basic-Utility Software. The study records are saved to the PC in EDF format and are available for analysis by third party software applications, such as Persyst Reveal (K011397).

    The X8 System combines hardware, firmware, and software to acquire physiological signals. It acquires physiological data through a battery powered headset worn by the patient and provides a flexible platform for applying sensors and acquiring signals from multiple locations on the head or body, transmitting and recording the signals, and providing visual and auditory indications to ensure high quality data are obtained.

    Model SP40 Sleep Profiler is applied by the patient to acquire and record electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG) signals, with optional accelerometer, acoustical, and photoplethysmographic signals during sleep. This model utilizes the X8 Sleep Profiler Strip.

    Model SP29 Sleep Profiler PSG2 is applied by the patient to acquire and record electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG) signals, with optional accelerometer, acoustical, and photoplethysmographic signals during sleep. This model additionally includes a nasal pressure transducer and cannula (for airflow), thoracic and abdomen respiratory effort, and pulse rate and oxyhemoglobin saturation from the finger. This model utilizes the X8 Sleep Profiler Strip.

    Model XS29 X8 Stat is applied by a technician to acquire, record, transmit, and/or display electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG) signals, with optional accelerometer, acoustical, and photoplethysmographic signals acquired during non-sleep conditions. This model utilizes either the X8 Midline or the X8 Referential strip.

    The Device Manager software application provides a means to communicate with the X8 Device, transfer study data, and format a device. The software transfers data saved in the memory of the X8 device using either a PC application or a web-based data entry application operating in a cloud server environment.

    The X-Series Basic-Utility Software acquires, presents, and stores physiological signals from the X8 Device. The software has a modular architecture that allows the users to interact using either the Graphical User Interface (GUI) provided with the installation, or programmatically via a Software Development Kit. Additional functionalities provided by X-Series Basic-Utility Software include impedance measurements, custom markers, and interface with the Bluetooth Receiving Dongle.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and study details based on the provided document:

    1. Table of Acceptance Criteria and Reported Device Performance

    Device: X8 System (Sleep Profiler (SP40), Sleep Profiler PSG2 (SP29), Stat X8 (XS29))
    Study Type: Prospective Comparison and Self-Application Study of X8 System Model SP29

    Acceptance Criterion (Primary Endpoint)Reported Device Performance and Outcome
    A) Comparison of Signals (X8 System airflow and respiratory effort vs. predicate device Compumedics Somte (K072201))
    No more than 10% of the breathing events recorded with the X8-PSG2 airflow signal were inferior to predicate signal.Achieved: No events recorded with the X8-PSG2 airflow signal (0%) were found inferior to the predicate signal.
    No more than 20% of the breathing events recorded with the X8-PSG2 respiratory effort will be inferior to the predicate signal.Achieved: The X8 thorax and abdomen belts were inferior to the predicate in only 4.0% (9/225) and 1.3% (3/232) of the events, respectively (both well below 20%).
    B) Demonstrate that high quality signals can be obtained when the X8 System is self-applied with the user instructions.
    At least 80% of subjects will be able to acquire at least one night of data (i.e., the entire period they were in bed).Achieved: 91% (10 of 11 subjects) were able to acquire at least one night of data for the entire night.
    At least 70% of each night of recording time will be valid across the oximetry, nasal pressure, and effort belt signals. (While not identified as a primary endpoint for cardio-respiratory signal quality, high EEG quality was also assessed.)Achieved: The percentage of good data obtained for oximetry, nasal pressure (airflow), and respiratory effort (thorax and abdomen) exceeded 90% on each night. High EEG quality was also obtained in over 90% of the recording time on each night.
    At least 70% of subjects did not report X8-PSG2 audio alerts (for signal quality) substantially affected (i.e., strongly agreed) their ability to stay asleep.Achieved: 90% (9 of 10 subjects) did not "strongly agree" that the PSG2 made it difficult for them to stay asleep. (Note: One subject was excluded from this calculation, resulting in 10 subjects for this specific endpoint, even though 11 were initially reported for data acquisition ability).

    2. Sample Size Used for the Test Set and Data Provenance

    • Test Set Sample Size:
      • For comparison of airflow and respiratory effort signals (part A of the study): The specific number of breathing events analyzed is provided (225 for thorax, 232 for abdomen), but the number of subjects contributing to these events is not explicitly stated.
      • For self-application and signal quality (part B of the study): 11 subjects.
      • For audio alerts acceptance criterion: 10 subjects (one subject was excluded from this analysis).
    • Data Provenance: The study was described as "prospective," indicating that the data was collected specifically for this study under controlled conditions defined prior to data collection. The document does not specify the country of origin for the data.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications

    The document does not explicitly state the number of experts or their qualifications for establishing the ground truth for this comparative study. However, the ground truth for part A (comparison of signals) was implicitly the readings from the predicate device, Compumedics Somte (K072201), an FDA-cleared device. For part B (self-application and signal quality), the ground truth for signal quality likely involved assessment against predefined criteria or by qualified personnel, but this is not detailed.

    4. Adjudication Method for the Test Set

    The document does not specify an explicit adjudication method (e.g., 2+1, 3+1). For the comparative study (part A), the comparison was against an "FDA cleared device," implying the predicate device's output served as the reference standard. For self-application (part B), signal quality was assessed, presumably against accepted norms for such physiological signals, but no multi-expert adjudication process is described.

    5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study Was Done, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

    No, a Multi Reader Multi Case (MRMC) comparative effectiveness study was not conducted or described in this document. The X8 System "acquires and displays physiological signals; no claims are being made for analysis of the acquired signals with respect to the accuracy, precision, and reliability." Therefore, this device does not involve AI analysis or human reader interpretation for diagnostic claims, but rather accurate signal acquisition.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

    The device's intended use is to "acquire, record, transmit, and display physiological signals." It does not include automated analysis or diagnostic algorithms. Therefore, a standalone algorithm performance study was not applicable and not done. The focus of the performance study was on the quality and equivalence of the acquired physiological signals.

    7. The Type of Ground Truth Used

    • For comparison of airflow and respiratory effort signals (Part A): The ground truth was based on the signals obtained from an FDA-cleared predicate device (Compumedics Somte (K072201)).
    • For self-application and signal quality (Part B): The ground truth for "valid" recording time and "high EEG quality" would have been established by assessing the acquired physiological signals against accepted physiological standards and criteria for signal integrity, likely by trained professionals. The specific method of establishing this ground truth is not detailed beyond the term "good data."

    8. The Sample Size for the Training Set

    The document describes "prospective studies" for verification and validation. Given that the device's function is signal acquisition and display, and no claims for analysis accuracy or reliability are being made, there isn't a "training set" in the context of machine learning. The studies described are performance evaluations of the hardware and software's ability to accurately capture and transmit signals.

    9. How the Ground Truth for the Training Set Was Established

    As noted above, no "training set" in the machine learning sense is described for this device. The ground truth for performance evaluation was established through comparison with a predicate FDA-cleared device and assessment against physiological signal quality standards.

    Ask a Question

    Ask a specific question about this device

    K Number
    K140190
    Device Name
    NIGHT SHIFT
    Date Cleared
    2014-05-29

    (125 days)

    Product Code
    Regulation Number
    872.5570
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Night Shift is indicated for prescription use for the treatment of adult patients with positional obstructive sleep apnea with a non-supine apnea-hypopnea index

    Device Description

    The Night Shift is worn around the neck to reduce the amount of time the user sleeps in the supine position as a treatment for positional obstructive sleep apnea. Night Shift combines hardware and firmware to detect when the user attempts to sleep in the supine position and can initiate vibro-tactile feedback with increasing intensity until the user shifts to a non-supine position. The initiation of positional feedback from the Night Shift is turned on is programmable to allow the user to fall asleep (if they must) on their back. Each night the Night Shift is worn, it monitors sleep position (% time supine), behavioral sleep efficiency, and snoring levels (% time snoring > 40 and 50 dB) as well as the frequency, duration and intensity of the feedback (when applied). These data can be optionally transferred via the USB port to the Night Shift Web Portal where the user can generate a report to assess how well the positional feedback is working. A "trial" protocol can include one night with no feedback to establish a baseline and two nights with feedback to assess compliance/efficacy. Utilization information is saved on the device that allows reports to be generated that compares daily use by month and monthly averages for one year. The portal also allows the device to be reformatted (to eliminate all previously recorded data) for a new user, adjust the feedback settings to a new user's personal preferences, and/or upgrade the firmware. For large healthcare organizations that limit internet access, desktop software is provided as an alternative to the portal.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the Advanced Brain Monitoring, Inc. Night Shift device, based on the provided text:

    Acceptance Criteria and Reported Device Performance

    EndpointAcceptance CriteriaReported Device PerformanceConclusion
    Effectiveness of Night Shift therapy (Primary)65% of PT compliant participants with baseline overall AHI > 10 and non-supine AHI 50% decrease in AHI.Met (85.2% vs. 65% target)
    Safety80% of participants will complete the study with no adverse events resulting in voluntary dropping.100% of compliant subjects successfully completed the study. No adverse events were reported.Met (100% vs. 80% target)
    Accuracy of Supine Position MeasurementComputation of percent time supine by Night Shift is within +/- 5% of the percent time supine by video recordings plus chest sensor in 73% of subjects.Night Shift was within 5% of chest/video supine time in 92% of the studies.Met (92% vs. 73% target)
    Treatment ComplianceAt least 80% of participants will be compliant (use Night Shift for a minimum of 5.5 hours/night or length of their time in bed, five nights/week).100% of the participants wore the Night Shift for a minimum of 20 nights across the 28 nights of intended use.Met (100% vs. 80% target)
    Reduction in Supine TimeAt least 70% of participants will average less than 15% time supine across the four weeks of home use.97% of the participants averaged less than 15% of time in bed in the supine position when therapy was delivered.Met (97% vs. 70% target)
    Improved Epworth Sleepiness Score (ESS)50% of PT compliant participants will show an improved ESS of ≥ 2.50% of participants exhibited an improvement of 2 or more, and 50% showed no change. None of the ESS scores worsened by 2 or more.Met (50% vs. 50% target, with no worsening)
    Improved Functional Outcomes of Sleep Questionnaire (FOSQ) totalFOSQ total will improve by ≥ 2 points in at least 50% of subjects.57% exhibited an improvement of 2 or more, 23% showed no change, and 20% showed a worsening of 2 or more.Met (57% vs. 50% target)
    Mean Sensitivity (sleep) and Specificity (wake) for Night ShiftThe mean sensitivity (sleep) and specificity (wake) for Night Shift will be 0.85 and 0.50, respectively.The endpoint was met based on the sensitivity and specificity of 90% and 58% across 65 studies.Met (90% sensitivity vs. 0.85, 58% specificity vs. 0.50)
    Night Shift Total Sleep Time (TST) within predicate range73% of subjects will be within the range of the predicate when subtracting PSG Total Sleep Time (TST) from Night Shift TST (i.e., range 151 and -129 minutes).99% of the studies had TST derived from Night Shift within the maximum error (based on two standard deviations of the TST error for the predicate device) vs. PSG TST.Met (99% vs. 73% target)
    Night Shift Sleep Efficiency (SE) within predicate range73% of subjects will be within the range of the predicate when subtracting PSG Sleep Efficiency (SE) from Night Shift SE (i.e., range 19.1 and -17.2%).92% of studies had SE values derived from Night Shift within the maximum error (based on two standard deviations of the SE error for the predicate device) vs. PSG SE. 80% of subjects had sleep onset values 50 dB to identify AHI ≥ 10 (sensitivity > 0.80, specificity > 0.65)**The percent time snoring > 50 dB can be used to identify patients with an AHI ≥ 10 with a sensitivity > 0.80 and a specificity > 0.65.
    Identification of treatment success/failure based on AHI, ESS, PHQ9, ISI, GAD7, FOSQThose successfully or unsuccessfully treated with Night Shift can be identified via a combination of changes in the AHI, daytime drowsiness (ESS), depression (PHQ9), Insomnia (ISI), anxiety (GAD7) and quality of life (FOSQ).Evaluating trends across these measures, 50% of subjects showed a substantial improvement as a result of Night Shift therapy and an additional 10% showed improvement, and 33% showed no change. None showed a worsening and two cases (7%) showed substantial overall worsening of subjective measures.Met (with caveat) - "numbers of failures were too few to characterize"

    Study Details for Clinical Tests:

    1. Sample size used for the test set and the data provenance:

      • Test Set Sample Size for Primary Effectiveness Endpoint: 27 patients with pre-treatment positional obstructive sleep apnea with a non-supine AHI 20).
      • Data Provenance: Not explicitly stated, but the study was a clinical study conducted to evaluate safety and efficacy, implying prospective data collection. The location (country of origin) is not mentioned.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • This information is not provided in the given text. Ground truth for sleep studies typically involves highly trained sleep technologists and physicians interpreting polysomnography (PSG) data. However, the document does not specify the number or qualifications for this particular study.
    3. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

      • This information is not provided in the given text.
    4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. The study evaluated the device's performance in treating sleep apnea and recording sleep parameters, not how human readers improve with or without AI assistance in interpreting diagnostic data from the device. The Night Shift is a therapeutic and monitoring device, not an AI diagnostic interpretation tool.
    5. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

      • Yes, the study primarily assessed the standalone performance of the Night Shift device. While it is a prescription device, its effectiveness was measured by its ability to reduce supine sleep and associated AHI, as well as its accuracy in measuring sleep parameters (position, TST, SE) independently. Human interaction is primarily for setup, compliance, and physician review of the generated reports, but the core therapeutic and monitoring function is standalone.
    6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

      • The ground truth for sleep parameters (AHI, supine time, TST, SE) appears to be Polysomnography (PSG), a gold standard for sleep disorder diagnosis. For the "Accuracy of Supine Position Measurement" endpoint, the ground truth was "video recordings plus chest sensor." For subjective measures (ESS, FOSQ), the ground truth was the participant's self-reported scores.
    7. The sample size for the training set:

      • This information is not provided in the given text. The document describes a clinical validation study, not the development or training phase of an algorithm.
    8. How the ground truth for the training set was established:

      • This information is not provided as the training set details are not mentioned.
    Ask a Question

    Ask a specific question about this device

    K Number
    K131383
    Date Cleared
    2013-11-27

    (197 days)

    Product Code
    Regulation Number
    882.1400
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The X-Series System is intended for prescription use in the home, healthcare facility, or clinical research environment to acquire, transmit, display and store physiological signals from patients ages 6 and older. The X-Series system requires operation by a trained technician. The X-Series System acquires, transmits, displays and stores electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG), and accelerometer signals. The X-Series System only acquires and displays physiological signals, no claims are being made for analysis of the acquired signals with respect to the accuracy, precision and reliability.

    Device Description

    The X-Series System is indicated for acquiring, transmitting, displaying and storing physiological data in patients. It can be used with ambulatory patients in the home, health care facility, or clinical research environment. The X-Series system requires operation by a trained technician. The X-Series System.is comprised the X10 and X24 Headsets and accessories, Synapse Cream, X-Series Basic Software and BT receiving unit. The X-Series Basic Software is also compatible with the Models X4-E, and X4-M (K130013) when used in wireless mode. The X-Series System combines hardware, firmware and software to acquire physiological signals. It acquires physiological data through a battery powered headset worn by the patient and provides a flexible platform for applying sensors using synapse cream and acquiring signals from multiple locations on the head or body, transmitting and recording the signals and providing visual indications to ensure high quality data are obtained. Model X24 provides for acquisition of twenty channels of electroencephalography (EEG) and four optional channels connected to two sensors via a dual-lead connector. Model X10 provides for acquisition of nine channels of electroencephalography (EEG) and an optional channel connected to two sensors via a dual-lead connector. Both models measure movement and position measured via a 3-D accelerometer. The device is designed so it can be affixed by a technician and displays the signals via a wireless connection during acquisition. The X-Series Basic software monitors signal quality to ensure that the sensors are properly applied and that high quality signals are being acquired. The X-Series Basic software provides a means to: a) initiate a study and track patient information, b) acquire and wirelessly transmit signals from the device, c) visually inspect the signal quality. The acquired signals are saved in a universal data format (European Data Format Plus, EDF+) that is intended to be analyzed by a Physician using FDA cleared third party software, i.e. Persyst Software (K011397).

    AI/ML Overview

    This document describes the X-Series System, an electroencephalograph device for acquiring, transmitting, displaying, and storing physiological data. The submission focuses on demonstrating substantial equivalence to a predicate device (K130013 X4 System) through non-clinical and limited clinical testing.

    Here's a breakdown of the requested information:

    1. Table of Acceptance Criteria and Reported Device Performance:

    The document leverages comparison to a predicate device and adherence to recognized standards as its primary acceptance criteria. Performance metrics are largely presented as being equivalent to the predicate.

    Acceptance Criteria CategorySpecific Criteria (from document)Reported Device Performance (X-Series System)
    Functional EquivalenceEquivalence to predicate device (X4 System) for electrophysiological (EEG, EOG, ECG, EMG), wireless acquisition, and actigraphy. Technologies used in the same manner.EEG: Sampling Rate: 256 s/s, 0.1 Hz High Pass (hardware), 100 Hz Low Pass (hardware), Dynamic range: +/- 1000μV, Resolution 0.03 µV, Peak to peak noise: 3.7 µV (typical), 110dB Common Mode Rejection Ratio (typically), Input Impedance: 100GOhm (Equivalent to X4)
    Aux - EOG/EMG: Sampling rate 256 Hz, 0.1 Hz High Pass (hardware), 100 Hz Low Pass (hardware).
    EMG/EOG: Dynamic range: +/- 1000μV, Resolution 0.03 μV, Peak to peak noise: 3.7 μV (typical) (Equivalent to X4)
    Aux - ECG: Bandwidth: 0.1 to 100Hz -3dB, Notch Filters: 50, 60Hz (software), Common Mode Rejection Ratio: 110dB, Input Impedance: 100GOhm, Input Range: +/-4mV, Accuracy: 16 bits, Noise:
    Ask a Question

    Ask a specific question about this device

    K Number
    K130007
    Device Name
    SLEEP PROFILER
    Date Cleared
    2013-04-17

    (105 days)

    Product Code
    Regulation Number
    882.1400
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Sleep Profiler is intended for the diagnostic evaluation by a physician to assess sleep quality in adults only. The Sleep Profiler is a software-only device to be used under the supervision of a clinician to analyze physiological signals and automatically score sleep study results, including the staging of sleep, detection of arousals and snoring.

    Device Description

    The Sleep Profiler is a software application that analyzes previously recorded physiological signals obtained during sleep. The Sleep Profiler software can analyze any EDF files meeting defined specifications, including signals acquired with the Advanced Brain Monitoring X4 System. Automated algorithms are applied to the raw signals in order to derive additional signals and interpret the raw and derived signal information. The software automates recognition of: a) sleep stage, b) snoring frequency and severity, c) pulse rate, d) cortical (EEG), sympathetic (pulse) and behavioral (actigraphy and snoring) arousals. A single channel of electrocardiography, electrooculargraphy, electromyography, or electroencephalography can be optionally presented for visual inspection and interpretation. The software identifies and rejects periods with poor electroencephalography signal quality. The full disclosure recording of derived signals and automated analyses can be visually inspected and edited prior to the results being integrated into a sleep study report. Medical and history information can be input from a questionnaire. Responses are analyzed to provide a pre-test probability of Obstructive Sleep Apnea (OSA) (a condition that cannot be diagnosed with Sleep Profiler) so an appropriate referral to a sleep physician is made. The automated analyses of physiological data are integrated with the questionnaire data, medical and history information to provide a comprehensive report. Several report formats are available depending on whether the user has acquired more than one night of data, wishes to obtain a narrative summary report or provide patient reports. The capability to enter or edit patient information, call the application to generate a study report, and/or download a report is provided using either the desktop PC application or in a web-based module which emulates the desktop functionality. The same analysis and report generation software is used for both the desktop and web-portal applications.

    AI/ML Overview

    The provided text describes a 510(k) submission for the Advanced Brain Monitoring, Inc. Sleep Profiler (K130007). This submission is for modifications to an already cleared device (K120450) to introduce a web-based module for patient information entry and report generation/download. The core analysis and report generation software remains unchanged from the predicate device.

    Therefore, the acceptance criteria and study information provided in this document focus exclusively on the non-clinical testing performed to demonstrate that the new web-based module functions equivalently to the desktop application. There is no clinical study described here that would involve human readers, ground truth establishment through expert consensus or pathology, or outcome data for performance metrics like sensitivity, specificity, etc.

    Here's a breakdown of the requested information based on the provided text:

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance Criteria (Key Metric for Software Verification)Reported Device Performance
    Confirmation of identical performance using either the desktop or portal for key functions:The results of the verification and validation activities demonstrate that the software meets requirements for safety, function, and intended use, including:
    - Enter questionnaire responses- Performance is identical for entering questionnaire responses via desktop or portal.
    - Edit study data- Performance is identical for editing study data via desktop or portal.
    - Initiate generation of a study report- Performance is identical for initiating generation of a study reports via desktop or portal.
    - Download a study report- Performance is identical for downloading study reports via desktop or portal.

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size for Test Set: Not explicitly stated. The verification and validation activities tested the functionality of the web-based module against the desktop application, indicating a comparative test of functionalities. It does not refer to a "test set" in the context of clinical data.
    • Data Provenance: Not applicable in the context of clinical data, as this was a non-clinical software verification study. The tests would have involved functional verification of the software.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

    • Not applicable. This submission focuses on software functionality verification, not clinical performance requiring expert ground truth.

    4. Adjudication Method for the Test Set

    • Not applicable. This was a non-clinical software verification, not a clinical study requiring adjudication of expert interpretations.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • No. An MRMC study was not conducted or described in this document. The submission explicitly states that "The modifications ... did not require clinical studies to support substantial equivalence."

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

    • Yes, indirectly. The Sleep Profiler is described as a "software-only device" that "automates recognition of: a) sleep stage, b) snoring frequency and severity, c) pulse rate, d) cortical (EEG), sympathetic (pulse) and behavioral (actigraphy and snoring) arousals." The verification discussed here specifically confirms that the web-based module performs these functions identically to the pre-existing desktop version, which does perform these analyses automatically without continuous human intervention during the analysis phase. However, it's intended to be "used under the supervision of a clinician" and the reporting can be "visually inspected and edited prior to the results being integrated into a sleep study report," implying a human-in-the-loop for final interpretation. The performance of the automated algorithm itself was established in the predicate device (K120450) and is not being re-evaluated for K130007.

    7. The Type of Ground Truth Used

    • Not applicable for clinical performance. For the software verification described, the "ground truth" was the expected functional output and behavior of the established desktop application (K120450). The web-based module was verified to produce identical results.

    8. The Sample Size for the Training Set

    • Not provided/not applicable. This submission does not discuss algorithmic development or training sets. It is a modification to an already existing software application. The predicate device (K120450) would have had this information.

    9. How the Ground Truth for the Training Set Was Established

    • Not provided/not applicable. As above, this information relates to the original algorithmic development, not the current submission for a web-based module.
    Ask a Question

    Ask a specific question about this device

    K Number
    K130013
    Device Name
    X4 SYSTEM
    Date Cleared
    2013-01-31

    (29 days)

    Product Code
    Regulation Number
    882.1400
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The X4 System is intended for prescription use in the home, healthcare facility, or clinical research environment to acquire, record, transmit and display physiological signals from adult patients. The X4 System acquires, records, transmits and displays electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG), accelerometer, acoustical and photoplethesmographic signals. The X4 system only acquires and displays physiological signals, no claims are being made for analysis of the acquired signals with respect to the accuracy, precision and reliability.

    Device Description

    The X4 system is used for configurable acquisition of physiological signals. Model X4-E provides for acquisition of three channels of electroencephalography (EEG) and one photoplethesmographic (PPG) signal from a head strip, with an optional channel connected to two sensors via a dual-lead connector with twice the gain. Model X4-M provides four channels of EEG with the dual-lead connector providing the input for reference sensors. Both models measure sound via an acoustic microphone, and movement and position measured via a 3-D accelerometer. The device is designed so it can be affixed by the patient and to record data. Alternatively, a technician can affix the device and display the signals via a wireless connection during acquisition. The X4 system firmware monitors signal quality to ensure that the sensors are properly applied and that high quality signals are being acquired.

    The X4 software provides a means to: a) initiate a study and track patient information, b) acquire and save signals to the memory of the device, c) acquire and wirelessly transmit signals from the device, d) upload data saved in the memory of the device to a PC, and e) visually inspect the signal quality.

    The acquired signals are saved in a universal data format (European Data Format - EDF). The study record, once saved on the PC, is available for analysis by Advanced Brain Monitoring's Sleep Profiler software application. The X4's downloaded study will reside on either or local PC or a cloud server, which can be a physical or virtual server. Software on the cloud server is accessed via web portal software.

    AI/ML Overview

    The Advanced Brain Monitoring, Inc. X4 System (K130013) is a device for configurable acquisition of physiological signals, including EEG, EOG, ECG, EMG, accelerometer, acoustical, and photoplethysmographic signals. It is intended for prescription use in various environments to acquire, record, transmit, and display these signals from adult patients.

    The documentation indicates that no clinical studies were performed to establish substantial equivalence for this particular submission (K130013). Instead, the determination of substantial equivalence was based on non-clinical tests, specifically focusing on risk management and software testing. The X4 System (K130013) is described as identical to a previously cleared X4 System (K120447), with the only change being the development of a Device Manager Module accessible via a web portal, which duplicates functions already present in the PC software.

    Therefore, the following information is based on the provided text, and it's important to note that the acceptance criteria and performance are related to the software functionality as evaluated for this specific 510(k) submission, rather than the accuracy of physiological signal acquisition, for which no new claims are being made.

    1. Table of Acceptance Criteria and Reported Device Performance

    Acceptance Criteria (Software Functionality)Reported Device Performance
    Format the device for a new patientConfirmed identical performance using either the desktop or web portal for this function. Software verification/validation activities demonstrated the software meets requirements for safety, function, and intended use.
    Enter and upload study identification information to the deviceConfirmed identical performance using either the desktop or web portal for this function. Software verification/validation activities demonstrated the software meets requirements for safety, function, and intended use.
    Download study information to data storageConfirmed identical performance using either the desktop or web portal for this function. Software verification/validation activities demonstrated the software meets requirements for safety, function, and intended use.
    Upload new firmwareConfirmed identical performance using either the desktop or web portal for this function. Software verification/validation activities demonstrated the software meets requirements for safety, function, and intended use.
    Ensure software meets requirements for safety, function, and intended useThe results of the verification and validation activities demonstrate that the software meets these requirements. This was confirmed by thorough testing through verification of specifications and validation, including software validation. The key metric was identical performance between the desktop and web portal for the specified key functions of the Device Manager software.

    2. Sample size used for the test set and the data provenance

    • Sample Size: The document does not specify a numerical sample size for the test set. The evaluation was based on "thoroughly tested through verification of specifications and validation, including software validation." This typically implies a systematic testing process of software functions rather than a patient-based test set size.
    • Data Provenance: Not applicable in the context of this software-focused non-clinical evaluation. The tests were performed on the software itself.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

    Not applicable. The ground truth for this software evaluation was the expected functional behavior of the software, as defined by its specifications. The evaluation confirmed whether the software performed these functions identically between two interfaces (desktop vs. web portal). This does not involve expert interpretation of data.

    4. Adjudication method for the test set

    Not applicable. As the testing focused on software functionality and identical performance, adjudication methods typically used in clinical studies (e.g., 2+1, 3+1) were not employed. The performance was assessed by direct comparison of software behavior.

    5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    No. An MRMC comparative effectiveness study was not done. The device does not involve AI for interpretation or human-in-the-loop assistance. The device is for signal acquisition and display only, and "no claims are being made for analysis of the acquired signals with respect to the accuracy, precision and reliability."

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    Yes, in a sense, but not for diagnostic interpretation. A standalone software functionality verification and validation was done for the Device Manager module. This evaluated the module's ability to perform its specified tasks (formatting device, uploading study info, downloading data, uploading firmware) independently and identically across different interfaces (desktop vs. web portal). This is an algorithm/software-only evaluation for its operational functions, not for clinical diagnostic performance.

    7. The type of ground truth used

    The ground truth used was the functional specifications and expected behavior of the Device Manager software. The verification and validation activities confirmed that the software's performance matched these predefined specifications, particularly that its functions were identical between the desktop and web portal versions.

    8. The sample size for the training set

    Not applicable. As this submission focused on software functionality and its equivalence to a predicate, there was no machine learning component, and thus, no "training set."

    9. How the ground truth for the training set was established

    Not applicable, as there was no training set.

    Ask a Question

    Ask a specific question about this device

    K Number
    K120450
    Device Name
    SLEEP PROFILER
    Date Cleared
    2012-09-19

    (218 days)

    Product Code
    Regulation Number
    882.1400
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Sleep Profiler is intended for the diagnostic evaluation by a physician to assess sleep quality in adults only. The Sleep Profiler is a software-only device to be used under the supervision of a clinician to analyze physiological signals and automatically score sleep study results, including the staging of sleep, detection of arousals and snoring.

    Device Description

    The Sleep Profiler is a software application that analyzes previously recorded physiological signals obtained during sleep. The Sleep Profiler software can analyze any EDF files meeting defined specifications, including signals acquired with the Advanced Brain Monitoring X4 System which is the subject of a separate 510(k). Automated algorithms are applied to the raw signals in order to derive additional signals and interpret the raw and derived signal information. The software automates recognition of: a) sleep stage, b) snoring frequency and severity, c) pulse rate, d) cortical (EEG), sympathetic (pulse) and behavioral (actigraphy and snoring) arousals. A single channel of electrocardiography, electrooculargraphy, electromyography, or electroencephalography can be optionally presented for visual inspection and interpretation. The software identifies and rejects periods with poor electroencephalography signal quality. The full disclosure recording of derived signals and automated analyses can be visually inspected and edited prior to the results being integrated into a sleep study report. Medical and history information can be input from a questionnaire. Responses are analyzed to provide a pre-test probability of Obstructive Sleep Apnea (OSA) (a condition that cannot be diagnosed with Sleep Profiler) so an appropriate referral to a sleep physician is made. The automated analyses of physiological data are integrated with the questionnaire data, medical and history information to provide a comprehensive report. Several report formats are available depending on whether the user has acquired more than one night of data, wishes to obtain a narrative summary report or provide patient reports.

    AI/ML Overview

    Here's a breakdown of the acceptance criteria and the study details for the Sleep Profiler device, based on the provided 510(k) summary:

    Acceptance Criteria and Device Performance

    The acceptance criteria are implied by the comparison to a predicate device, MICHELE (K112102). The goal is to demonstrate "similar" performance. The specific metrics are overall percent agreement and agreement for each sleep stage.

    Table 1: Sleep Profiler Performance vs. Predicate Device Performance (Sleep Staging)

    MetricSleep Profiler Performance Data (from 44 subjects)Predicate Device (MICHELE, K112102) Performance Data (from its study)
    Overall % AgreementNot explicitly stated as an overall value, but individual positive and negative agreements are provided.82.6%
    Agreement by Sleep Stage (Positive Agreement / Sensitivity)
    Wake0.7989.9%
    N10.4050.4%
    N20.8082.9%
    N30.7682.9%
    REM0.7289.8%
    Agreement by Sleep Stage (Negative Agreement / Specificity)
    Wake0.9596.4%
    N10.9194.7%
    N20.8389.6%
    N30.9797.5%
    REM0.9798.5%

    The summary states, "The positive and negative percent agreement obtained during clinical validation of the Sleep Profiler are similar to that obtained by the predicate device, MICHELE (K112102), which was validated using a different data set."

    Study Details

    1. Sample Size used for the test set and the data provenance:

      • Test Set Sample Size: 44 subjects.
      • Data Provenance: Not explicitly stated, but it's a "clinical validation" comparing to manual observation. It doesn't state whether it's retrospective or prospective, or the country of origin.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • Number of Experts: Three raters.
      • Qualifications: "either sleep technicians or physicians."
    3. Adjudication method for the test set:

      • The table indicates a "No-Consensus" row for the experts, implying adjudication by consensus was used. Specifically, the "Epochs assigned by Expert Scoring" includes a "No-Consensus" category (653 epochs out of 39191 total), suggesting that if the three raters did not agree, those epochs were excluded from the primary agreement calculations for individual stages. The main performance metrics are likely based on epochs where there was full consensus (3 out of 3, or potentially 2 out of 3 if that's what "consensus" meant here, although the "No Consensus" row suggests agreement was required).
    4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No, an MRMC comparative effectiveness study was not done. The study's purpose was to validate the "sleep staging algorithms by comparison to sleep staging made by manual observation by three raters." This is a standalone algorithm performance study compared to human experts as ground truth, not a study evaluating human performance with or without AI assistance.
    5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

      • Yes, a standalone algorithm performance study was done. The results presented in the table ("Epochs assigned by Sleep Profiler" vs. "Epochs assigned by Expert Scoring") directly report the algorithm's performance without human interaction or modification. The description also states the software "automates recognition" and that the "full disclosure recording of derived signals and automated analyses can be visually inspected and edited prior to the results being integrated into a sleep study report," but the presented validation data is for the automated algorithm's output.
    6. The type of ground truth used:

      • Expert Consensus. The ground truth for the test set was established by the "manual observation by three raters who were either sleep technicians or physicians."
    7. The sample size for the training set:

      • Not specified. The document does not provide details about the training set size or how it was established. It only discusses the clinical validation (test set) of the software.
    8. How the ground truth for the training set was established:

      • Not specified. Since details about the training set are not provided, how its ground truth was established is also not mentioned.
    Ask a Question

    Ask a specific question about this device

    K Number
    K120447
    Device Name
    X4
    Date Cleared
    2012-06-20

    (127 days)

    Product Code
    Regulation Number
    882.1400
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The X4 System is intended for prescription use in the home, healthcare facility, or clinical research environment to acquire, record, transmit and display physiological signals from adult patients. The X4 System acquires, records, transmits and displays electroencephalogram (EEG), electrooculogram (EOG), electrocardiogram (ECG), and/or electromyogram (EMG), accelerometer, acoustical and photoplethesmographic signals. The X4 system only acquires and displays physiological signals, no claims are being made for analysis of the acquired signals with respect to the accuracy, precision and reliability.

    Device Description

    The X4 system is used for configurable acquisition of physiological signals. Model X4-E provides for acquisition of three channels of electroencephalography (EEG) and one photoplethesmographic (PPG) signal from a head strip, with an optional channel connected to two sensors via a dual-lead connector with twice the gain. Model X4-M provides four channels of EEG with the dual-lead connector providing the input for reference sensors. Both models measure sound via an acoustic microphone, and movement and position measured via a 3-D accelerometer. The device is designed so it can be affixed by the patient and to record data. Alternatively, a technician can affix the device and display the signals via a wireless connection during acquisition. The X4 system firmware monitors signal quality to ensure that the sensors are properly applied and that high quality signals are being acquired.

    The X4 software provides a means to: a) initiate a study and track patient information, b) acquire and save signals to the memory of the device, c) acquire and wirelessly transmit signals from the device, d) upload data saved in the memory of the device to a PC, and e) visually inspect the signal quality.

    The acquired signals are saved in a universal data format (European Data Format – EDF) that is intended to be analyzed with third party software, including Advanced Brain Monitoring's Sleep Profile Software (K120450).

    AI/ML Overview

    The provided text describes the X4 System, a device for acquiring physiological signals. The 510(k) summary focuses on demonstrating substantial equivalence to predicate devices through non-clinical testing and a limited clinical study.

    Here's an analysis of the acceptance criteria and study information provided:

    Acceptance Criteria and Reported Device Performance

    The core acceptance criterion for the X4 System, as articulated in the clinical tests, is based on the interpretability of the acquired signals and the ease of device application.

    Acceptance CriteriaReported Device Performance
    Non-Clinical:
    Compliance with system-level requirementsAll features of the X4 System were compliant with the system level requirements.
    Electrical, biological safety, performance, and software testsConfirmation of conformity to FDA recognized consensus standards and voluntary standards (IEC 60601-1-1, IEC 60601-1-2, ISO 10993-1, IEC 60601-1-11, IEC 60601-2-26).
    Signals provide similar information to predicate device for physician interpretationSignals acquired with the X4 System provide similar information as compared to the predicate device that would allow a physician to interpret the signals. (Specific metrics or comparison data are not provided in this summary.)
    Clinical:
    Over 90% of overnight studies recorded with the X4 are interpretable and behave as expectedResult: Over 90% of studies recorded overnight with the X4 are interpretable and behave as expected.
    Device instructions can be applied without difficulty by patients in the homeResult: The X4 instructions were applied without difficulty, allowing all subjects to properly apply the device so that it remained in the proper position and allowing any problems that triggered an audio alarm to be properly resolved. (No specific quantitative metric for "difficulty" or "proper application" is given beyond the qualitative statement.)

    Study Details for Acceptance Criteria

    2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

    • Test set sample size: While a specific number for the sample size for the clinical test is not explicitly stated, it refers to "all subjects" and "over 90% of studies recorded overnight." This suggests a prospective clinical study involving multiple subjects.
    • Data provenance: Not explicitly stated, but the context of a 510(k) submission to the FDA for a US company suggests it would likely involve data from the US, potentially a prospective clinical trial.

    3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

    • The summary states that "signals acquired with the X4 System provide similar information as compared to the predicate device that would allow a physician to interpret the signals." and that "over 90% of studies recorded overnight with the X4 are interpretable."
    • This implies that physicians are the experts who would interpret the signals to determine interpretability. However, the number of experts and their specific qualifications (e.g., board-certified sleep physicians, neurologists, years of experience) are not specified in the provided text.

    4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

    • The text does not specify an adjudication method. It mentions that "physicians" would interpret the signals, but it does not detail how potential disagreements among interpreters would be resolved or if multiple interpreters were used for each case.

    5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

    • No, an MRMC comparative effectiveness study was not done.
    • The X4 System is described as a device for acquiring, recording, transmitting, and displaying physiological signals, with "no claims being made for analysis of the acquired signals with respect to the accuracy, precision and reliability." This indicates that the device itself does not perform AI-assisted analysis and therefore, a study on human reader improvement with AI assistance would not be applicable to this submission.

    6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

    • No, a standalone (algorithm only) performance study was not done.
    • The device's intended use is to acquire, record, transmit, and display physiological signals. It explicitly states "no claims are being made for analysis of the acquired signals." Thus, there is no standalone algorithm being evaluated for diagnostic or analytical performance.

    7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

    • The ground truth for the clinical study appears to be expert interpretation (physician interpretability) of the acquired signals. The study aimed to demonstrate that the signals are "interpretable" and "behave as expected," which would rely on a physician's assessment.

    8. The sample size for the training set

    • Not applicable / Not provided. The X4 System is a signal acquisition and display device, not an analytical or AI-driven system. Therefore, it does not involve a "training set" in the context of machine learning algorithms.

    9. How the ground truth for the training set was established

    • Not applicable. As a signal acquisition device without analytical claims, there is no training set or associated ground truth establishment process for algorithm training.
    Ask a Question

    Ask a specific question about this device

    K Number
    K112514
    Date Cleared
    2012-01-09

    (132 days)

    Product Code
    Regulation Number
    868.2375
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Apnea Risk Evaluation System (ARES™), Model 610 is indicated for use in the diagnostic evaluation by a physician of adult patients with possible sleep apnea. The ARES™ can record and score respiratory events during sleep (e.g., apneas, hypopneas, mixed apneas and flow limiting events). The device is designed for prescription use in home diagnosis of adults with possible sleep-related breathing disorders.

    Device Description

    The Apnea Risk Evaluation System (ARES™) includes a device called a Unicorder which records oxygen saturation, pulse rate, snoring level, head movement and head position, and airflow. Additionally, a physiological signal from the forehead used to stage sleep or respiratory effort signal obtained from an optional piezo respiratory effort belt can be acquired. The battery powered Unicorder provides sufficient capacity to record two nights of data. The device monitors signal quality during acquisition and notifies the user via voice messages when adjustments are required. A standard USB cable connects the Unicorder to a USB port on a host computer when patient data is to be uploaded or downloaded. The USB cable provides power to the Unicorder during recharging from the host computer or from a USB wall charger. The Unicorder cannot record nor can it be worn by the patient when connected to the host computer or the wall charger. Software, residing on a local PC or a physical or virtual server controls the uploading and downloading of data to the Unicorder, processes the sleep study data and generates a sleep study report. The ARES™ can auto-detect positional and non-positional obstructive and mixed apneas and hypopneas similarly to polysomnography. It can detect sleep/wake and REM and non-REM. After the sleep study has been completed, data is transferred off the Unicorder is prepared for the next study. The downloaded sleep study record is then processed with the ARES™ Insight software to transform the raw signals and derive and assess changes in oxygen saturation (SpO2), pulse rate, head movement, head position, snoring sounds, airflow, and EEG or respiratory effort. The red and IR signals are used to calculate the SpO2 and pulse rate. The actigraphy signals are transformed to obtain head movement and head position. A clinician can convert an auto-detected obstructive apnea to a central apnea based on visual inspection of the waveforms. ARES™ Screener can predict pre-test probability of obstructive sleep apnea (OSA). The ARES™ can also assist the physician to identify patients who will likely have a successful OSA treatment outcome, including CPAP and oral appliance therapies. ARES™ can help identify patients who would benefit from a laboratory PAP titration.

    AI/ML Overview

    The provided FDA 510(k) summary for the Apnea Risk Evaluation System (ARES™), Model 610 (K112514) primarily focuses on demonstrating substantial equivalence to a predicate device rather than providing a detailed study proving the device meets specific acceptance criteria in a standalone performance evaluation. The changes in the modified device are related to software platform, improved filtering of the SpO2 signal, and new claims in the report messages.

    Here's an attempt to extract and organize the information based on your request, with significant caveats that much of the requested detail is not explicitly provided in the document for the performance of the modified device in the way you've outlined:


    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria are primarily for the SpO2 accuracy after the filtering changes. The document explicitly states that the accuracy in all ranges is less than 3.5% as recommended by draft FDA guidance.

    Acceptance Criteria (Modified Device)Reported Device Performance (Modified Device)
    SpO2 Accuracy (Arms) for various ranges:
    60-100%
    Ask a Question

    Ask a specific question about this device

    K Number
    K111110
    Device Name
    APNEA GUARD
    Date Cleared
    2011-07-22

    (93 days)

    Product Code
    Regulation Number
    872.5570
    Reference & Predicate Devices
    Why did this record match?
    Applicant Name (Manufacturer) :

    ADVANCED BRAIN MONITORING, INC.

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The Apnea Guard is a mandibular repositioning device intended to reduce or alleviate snoring and mild to moderate obstructive sleep apnea (OSA) in patients 18 years and older. The Apnea Guard is intended to be fitted with assistance from a healthcare professional, and used during sleep for less than 30-nights.

    Device Description

    The Apnea Guard is a Mandibular Repositioning Device (MRD) which consists of interlocking upper and lower trays filled with silicone retention material fitted to the patient. The useful life of the retention material will limit the Apnea Guard's used to a temporary appliance, less than 30 days. The trays are locked into a position that advances the mandible for the treatment of snoring and / or obstructive sleep apnea. The one-size-fits-all appliance is able to accommodate the full range of dental etiologies, including wide and narrow arches, missing or compromised teeth and gums, etc.

    AI/ML Overview

    This document describes the acceptance criteria and the study that demonstrates the Apnea Guard device meets these criteria.

    1. Table of Acceptance Criteria and Reported Device Performance

    The provided document does not explicitly present a table of "acceptance criteria" for the Apnea Guard in a quantitative manner that can be directly mapped to the study's performance results. Instead, it frames the performance in terms of "substantial equivalence" to a predicate device (Airway Management TAP III). The key performance indicator highlighted is the reduction in Apnea-Hypopnea Index (AHI).

    Therefore, the table below reflects this comparative performance for the critical metric mentioned:

    Acceptance Criteria (Implied by Substantial Equivalence)Reported Device Performance (Apnea Guard)
    Statistically significant reduction in overall and supine AHI (equivalent to predicate device).Statistically significant reduction in overall and supine AHI, found to be equivalent to custom appliance. 56% showed > 50% reduction in overall AHI, and 63% showed > 50% reduction in supine AHI.
    Reduce sleep disordered breathing, hypoxemia, snoring, and sympathetic arousals.Demonstrated equivalence to the predicate in reducing sleep disordered breathing, hypoxemia, snoring, and sympathetic arousals.

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size: Eighteen patients.
    • Data Provenance: The study was "prospective." The document does not explicitly state the country of origin, but given the FDA 510(k) submission, it is highly likely to be a study conducted within the United States or under international clinical trial standards acceptable to the FDA.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

    The document does not specify the number or qualifications of experts (e.g., sleep physicians, polysomnography technologists) involved in establishing the ground truth for the test set. It mentions that patients underwent a "two-night Qualification Home Sleep Test (HST)" and that "Measurement and recording of Apnea Index, Apnea-Hypopnea Index, Hypoxemia, Snoring, and Sympathetic Arousals was done." This implies that standard diagnostic procedures for sleep disorders, typically interpreted by trained professionals, were followed.

    4. Adjudication Method for the Test Set

    The document does not describe a specific adjudication method (e.g., 2+1, 3+1) for the test set data. The collection of AHI, hypoxemia, snoring, and sympathetic arousal data likely followed standard polysomnography scoring rules, which inherently involve a defined process for data interpretation, but not necessarily a multi-reader adjudication process as seen in some AI studies.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance?

    No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. The study was a clinical study comparing the Apnea Guard (the proposed device) against a predicate device (Airway Management TAP III) in terms of its effectiveness in reducing sleep-disordered breathing. It does not involve human readers interpreting data with or without AI assistance.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

    The Apnea Guard is a physical mandibular repositioning device, not an algorithm or software. Therefore, the concept of a "standalone" algorithmic performance study is not applicable. The device itself is the "standalone" intervention being tested.

    7. The Type of Ground Truth Used

    The ground truth for the clinical performance was established using physiological measurements and clinical assessments derived from sleep studies. Specifically, "Apnea Index, Apnea-Hypopnea Index, Hypoxemia, Snoring, and Sympathetic Arousals" were measured and recorded. These metrics are objective physiological indicators of sleep-disordered breathing.

    8. The Sample Size for the Training Set

    No training set is mentioned as the Apnea Guard is a physical medical device, not an AI/ML algorithm that requires a training phase.

    9. How the Ground Truth for the Training Set was Established

    Not applicable, as there is no training set for this type of device.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 2